Abstract

The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation. Here, we identify an additional activity of R-2-HG: tumor cell–derived R-2-HG is taken up by T cells where it induces a perturbation of nuclear factor of activated T cells transcriptional activity and polyamine biosynthesis, resulting in suppression of T cell activity. IDH1-mutant gliomas display reduced T cell abundance and altered calcium signaling. Antitumor immunity to experimental syngeneic IDH1-mutant tumors induced by IDH1-specific vaccine or checkpoint inhibition is improved by inhibition of the neomorphic enzymatic function of mutant IDH1. These data attribute a novel, non-tumor cell-autonomous role to an oncometabolite in shaping the tumor immune microenvironment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Yang, M., Soga, T. & Pollard, P. J. Oncometabolites: Linking altered metabolism with cancer. J. Clin. Invest. 123, 3652–3658 (2013).

  2. 2.

    Erez, A. & DeBerardinis, R. J. Metabolic dysregulation in monogenic disorders and cancer—finding method in madness. Nat. Rev. Cancer 15, 440–448 (2015).

  3. 3.

    Pollard, P. J. et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231–2239 (2005).

  4. 4.

    Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).

  5. 5.

    Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).

  6. 6.

    Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).

  7. 7.

    Mullen, A. R. & DeBerardinis, R. J. Genetically-defined metabolic reprogramming in cancer. Trends Endocrinol. Metab. 23, 552–559 (2012).

  8. 8.

    Bardella, C. et al. Expression of Idh1R132H in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis. Cancer Cell 30, 578–594 (2016).

  9. 9.

    Kaelin, W. G.Jr. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 76, 335–345 (2011).

  10. 10.

    Waitkus, M. S., Diplas, B. H. & Yan, H. Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol. 18, 16–26 (2016).

  11. 11.

    Leonardi, R., Subramanian, C., Jackowski, S. & Rock, C. O. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J. Biol. Chem. 287, 14615–14620 (2012).

  12. 12.

    Grassian, A. R. et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 74, 3317–3331 (2014).

  13. 13.

    Sasaki, M. et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 26, 2038–2049 (2012).

  14. 14.

    Tateishi, K. et al. Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell 28, 773–784 (2015).

  15. 15.

    Reitman, Z. J. et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl Acad. Sci. USA 108, 3270–3275 (2011).

  16. 16.

    Esmaeili, M. et al. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma. Cancer Res. 74, 4898–4907 (2014).

  17. 17.

    Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178–184 (2015).

  18. 18.

    Fu, X. et al. 2-Hydroxyglutarate inhibits ATP synthase and mTOR signaling. Cell Metab. 22, 508–515 (2015).

  19. 19.

    Su, R. et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling. Cell 172, 90–105 (2018).

  20. 20.

    Fathi, A. T. et al. Elevation of urinary 2-hydroxyglutarate in IDH-mutant glioma. Oncologist 21, 214–219 (2016).

  21. 21.

    Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324–327 (2014).

  22. 22.

    Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626–630 (2013).

  23. 23.

    Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626 (2013).

  24. 24.

    Pusch, S. et al. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol. 133, 629–644 (2017).

  25. 25.

    Losman, J. A. & Kaelin, W. G.Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836–852 (2013).

  26. 26.

    Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2011).

  27. 27.

    Muhlhausen, C. et al. Membrane translocation of glutaric acid and its derivatives. J. Inherit. Metab. Dis. 31, 188–193 (2008).

  28. 28.

    Pajor, A. M. & Randolph, K. M. Inhibition of the Na+/dicarboxylate cotransporter by anthranilic acid derivatives. Mol. Pharmacol. 72, 1330–1336 (2007).

  29. 29.

    Kolker, S. et al. NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria. Eur. J. Neurosci. 16, 21–28 (2002).

  30. 30.

    Latini, A. et al. Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues. Mol. Genet. Metab. 86, 188–199 (2005).

  31. 31.

    Schumacher, T., Bunse, L., Wick, W. & Platten, M. Mutant IDH1: an immunotherapeutic target in tumors. Oncoimmunology 3, e974392 (2014).

  32. 32.

    Brown, C. E. et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062–4072 (2015).

  33. 33.

    Duncan, C. G. et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 22, 2339–2355 (2012).

  34. 34.

    Wick, W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874–5880 (2009).

  35. 35.

    Wick, W. et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 18, 1529–1537 (2016).

  36. 36.

    Amankulor, N. M. et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 31, 774–786 (2017).

  37. 37.

    Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 127, 1425–1437 (2017).

  38. 38.

    Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015).

  39. 39.

    Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells. Immunity 42, 265–278 (2015).

  40. 40.

    Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T Cell responses. Cell 162, 1217–1228 (2015).

  41. 41.

    Ledderose, C. et al. Mitochondria are gate-keepers of T cell function by producing the ATP that drives purinergic signaling. J. Biol. Chem. 289, 25936–25945 (2014).

  42. 42.

    Blagih, J. et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42, 41–54 (2015).

  43. 43.

    Chan, A. Y. et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem. 283, 24194–24201 (2008).

  44. 44.

    Passariello, C. L. et al. Evidence that AMP-activated protein kinase can negatively modulate ornithine decarboxylase activity in cardiac myoblasts. Biochim. Biophys. Acta 1823, 800–807 (2012).

  45. 45.

    Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871–882 (2011).

  46. 46.

    Ray, R. M., Bavaria, M. & Johnson, L. R. Interaction of polyamines and mTOR signaling in the synthesis of antizyme (AZ). Cell Signal. 27, 1850–1859 (2015).

  47. 47.

    Bunse, L. et al. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J. Clin. Invest. 125, 593–606 (2015).

  48. 48.

    Pellegatta, S. et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol. Commun. 3, 4 (2015).

  49. 49.

    Reardon, D. A. et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol. Res. 4, 124–135 (2016).

  50. 50.

    Chen, J. Y. et al. The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. Sci. Rep. 6, 32428 (2016).

  51. 51.

    Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).

  52. 52.

    Tyrakis, P. A. et al. S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate. Nature 540, 236–241 (2016).

  53. 53.

    Olivera-Bravo, S. et al. Striatal neuronal death mediated by astrocytes from the Gcdh−/− mouse model of glutaric acidemia type I. Hum. Mol. Genet. 24, 4504–4515 (2015).

  54. 54.

    Karlstaedt, A. et al. Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc. Natl Acad. Sci. USA 113, 10436–10441 (2016).

  55. 55.

    Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458–468 (2015).

  56. 56.

    Harrington, L. E., Janowski, K. M., Oliver, J. R., Zajac, A. J. & Weaver, C. T. Memory CD4 T cells emerge from effector T-cell progenitors. Nature 452, 356–360 (2008).

  57. 57.

    Campos, B. et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin. Cancer Res. 16, 2715–2728 (2010).

  58. 58.

    Kumai, T. et al. Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol. Res. 5, 72–83 (2017).

  59. 59.

    Jha, A. K. et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42, 419–430 (2015).

  60. 60.

    Buescher, J. M., Moco, S., Sauer, U. & Zamboni, N. Ultrahigh performance liquid chromatography-tandem mass spectrometry method for fast and robust quantification of anionic and aromatic metabolites. Anal. Chem. 82, 4403–4412 (2010).

  61. 61.

    Balss, J. et al. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol. 124, 883–891 (2012).

  62. 62.

    Barber, T. W., Brockway, J. A. & Higgins, L. S. The density of tissues in and about the head. Acta Neurol. Scand. 46, 85–92 (1970).

  63. 63.

    Sahm, F. et al. Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. Brain Pathol. 22, 26–31 (2012).

  64. 64.

    Burstenbinder, K., Rzewuski, G., Wirtz, M., Hell, R. & Sauter, M. The role of methionine recycling for ethylene synthesis in Arabidopsis. Plant J. 49, 238–249 (2007).

  65. 65.

    Shi, W., Oshlack, A. & Smyth, G. K. Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. Nucleic Acids Res. 38, e204 (2010).

  66. 66.

    Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 3 (2004).

  67. 67.

    Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27–30 (2000).

  68. 68.

    Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457–462 (2016).

  69. 69.

    Hummel, M., Meister, R. & Mansmann, U. GlobalANCOVA: exploration and assessment of gene group effects. Bioinformatics 24, 78–85 (2008).

  70. 70.

    Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).

  71. 71.

    Sahm, F. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 18, 682–694 (2017).

Download references

Acknowledgements

We acknowledge the support of the DKFZ Light Microscopy Facility, the microarray unit of the DKFZ Genomics and Proteomics Core Facility, the Transgenic Service of the Center for Preclinical Research, DKFZ, and the DKFZ–Bayer Alliance. We thank the Metabolomics Core Technology Platform of the Excellence Cluster CellNetworks for support with UPLC-based metabolite quantification. The results published here are in part based on data generated by the TCGA Research Network: http://cancergenome.nih.gov/. A2DR1 mice were provided by Institute Pasteur. We thank S. Kircher for flow cytometric analyses; H.Y. Ngyuen, L. Dörner, K. Rauschenbach, and M. Fischer for technical support; and J. Jung for graphics design. This work was supported by the epigenetics@dkfz program to L.B., the DKFZ-MOST program (project number 2526) and the Helmholtz Program Immunology and Inflammation, the Dr. Rolf M. Schwiete Foundation and the German Research Foundation (DFG) (FOR2289: PL315/3-1), the Sonderförderlinie ‘Neuroinflammation’ of the Ministry of Science of Baden Württemberg and the German Ministry of Education and Science (National Center for Tumor Diseases Heidelberg NCT 3.0 program ‘Precision immunotherapy of brain tumors’ and the DKTK program) to M.Pl. the Joint Funding Program MGH-Heidelberg Alliance in Neuro-Oncology to M.Pl. and M.S., the Wilhelm Sander Foundation (2012.118.1) and the German Cancer Aid (70112399) to M.Pl. and A.v.D., the German Cancer Aid (110624) to W.W., the ZUK 49/2 from the DFG to G.P., FOR2289 to B.A.N. and D.A., SFB894 to B.A.N., and the German Cancer Aid to S.T.. L.B. and M.F. are members of the MD/PhD program at Heidelberg University. L.B. was funded by Heidelberg Medical Faculty. T.B., K.S., J.K.S., and M.Ki. are supported by the Helmholtz International Graduate School, T.B. is supported by the Medical Faculty and University Hospital Mannheim. F.S. is supported by a postdoctoral fellowship of the University Hospital Heidelberg. B.W. is supported by the Faculty of Medicine of the Technical University of Munich (KKF grant). E.G. is supported by a Marie-Curie fellowship.

Author information

Author notes

  1. These authors contributed equally: Lukas Bunse, Stefan Pusch, Theresa Bunse.

Affiliations

  1. German Cancer Consortium (DKTK) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany

    • Lukas Bunse
    • , Theresa Bunse
    • , Khwab Sanghvi
    • , Mirco Friedrich
    • , Jana K. Sonner
    • , Edward Green
    • , Katrin Deumelandt
    • , Michael Kilian
    • , Anna von Landenberg
    • , Michael O. Breckwoldt
    • , Simone Karcher-Bausch
    • , Iris Oezen
    • , Magdalena Kramer
    •  & Michael Platten
  2. Department of Neurology, Heidelberg University Medical Center, Heidelberg, Germany

    • Lukas Bunse
    • , Tobias Kessler
    • , Wolfgang Wick
    •  & Michael Platten
  3. National Center for Tumor Diseases Heidelberg, DKTK, Heidelberg, Germany

    • Lukas Bunse
    • , Theresa Bunse
    • , Tobias Kessler
    • , Wolfgang Wick
    •  & Michael Platten
  4. Faculty of Biosciences, Heidelberg University, Heidelberg, Germany

    • Lukas Bunse
    • , Khwab Sanghvi
    • , Katrin Deumelandt
    • , Michael Kilian
    •  & Andreas von Deimling
  5. Department of Neuropathology, Heidelberg University Medical Center, Heidelberg, Germany

    • Stefan Pusch
    • , Felix Sahm
    • , Jochen Meyer
    • , Antje Habel
    • , Jessica Eisel
    • , Daniel Schrimpf
    •  & Andreas von Deimling
  6. DKTK CCU Neuropathology, DKFZ, Heidelberg, Germany

    • Stefan Pusch
    • , Felix Sahm
    • , Jochen Meyer
    • , Antje Habel
    • , Jessica Eisel
    •  & Daniel Schrimpf
  7. Department of Neurology, University Hospital and Medical Faculty Mannheim, Mannheim, Germany

    • Theresa Bunse
    •  & Michael Platten
  8. Molecular Biophysics, Center for Integrative Physiology and Molecular Medicine, School of Medicine, Saarland University, Homburg, Germany

    • Dalia Alansary
    •  & Barbara A. Niemeyer
  9. Broad Institute of Harvard and MIT and Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    • Cyril Neftel
    •  & Mario L. Suvà
  10. FlowCore Mannheim and Institute of Transfusion Medicine and Immunology, Mannheim, Germany

    • Stefanie Uhlig
    •  & Karen Bieback
  11. DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany

    • Tobias Kessler
    • , Anna S. Berghoff
    • , Miriam Ratliff
    •  & Wolfgang Wick
  12. Institute of Neurology, Medical University of Vienna, Vienna, Austria

    • Anna S. Berghoff
  13. CNS Tumors Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    • Anna S. Berghoff
    •  & Matthias Preusser
  14. Agios Pharmaceuticals, Inc., Cambridge, MA, USA

    • Kelly Marsh
    • , Mya Steadman
    • , Dongwei Zhu
    • , Brandon Nicolay
    •  & Marion Dorsch
  15. Department of Diagnostic and Interventional Neuroradiology, Neuro-Kopf-Zentrum, Klinikum rechts der Isar, Technical University Munich, Munich, Germany

    • Benedikt Wiestler
  16. Department of Neuroradiology, Heidelberg University Medical Center, Heidelberg, Germany

    • Michael O. Breckwoldt
  17. Max Eder Junior Group on Low Grade Gliomas, Heidelberg University Medical Center, Heidelberg, Germany

    • Ruslan Al-Ali
    •  & Sevin Turcan
  18. DNA Vectors Unit, DKFZ, Heidelberg, Germany

    • Matthias Bozza
    •  & Richard Harbottle
  19. Center for Organismal Studies, University Heidelberg, Heidelberg, Germany

    • Gernot Poschet
  20. Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland

    • Michael Weller
  21. Department for Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria

    • Matthias Preusser
  22. Department of Neurosurgery, Stuttgart Clinics, Stuttgart, Germany

    • Minou Nadji-Ohl
  23. Department of Neurosurgery, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany

    • Niklas Thon
  24. Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany

    • Michael C. Burger
  25. DKTK Partner Site Frankfurt/Mainz, Frankfurt, Germany

    • Michael C. Burger
    • , Patrick N. Harter
    •  & Karl H. Plate
  26. Institute of Neurology (Edinger Institute), University Hospital and Medical Faculty, Goethe University, Frankfurt, Germany

    • Patrick N. Harter
    •  & Karl H. Plate
  27. Neurosurgery Clinic, University Hospital Mannheim, Mannheim, Germany

    • Miriam Ratliff
    •  & Daniel Hänggi
  28. Division of Biostatistics, DKFZ, Heidelberg, Germany

    • Axel Benner
  29. Metabolic Center Heidelberg, University Children’s Hospital, Heidelberg, Germany

    • Jürgen Okun
  30. Division of Experimental Neurosurgery, Department of Neurosurgery, Heidelberg University Medical Center, Heidelberg, Germany

    • Christel Herold-Mende
  31. Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany

    • Stefan Kaulfuss
    •  & Holger Hess‐Stumpp
  32. Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    • Daniel P. Cahill

Authors

  1. Search for Lukas Bunse in:

  2. Search for Stefan Pusch in:

  3. Search for Theresa Bunse in:

  4. Search for Felix Sahm in:

  5. Search for Khwab Sanghvi in:

  6. Search for Mirco Friedrich in:

  7. Search for Dalia Alansary in:

  8. Search for Jana K. Sonner in:

  9. Search for Edward Green in:

  10. Search for Katrin Deumelandt in:

  11. Search for Michael Kilian in:

  12. Search for Cyril Neftel in:

  13. Search for Stefanie Uhlig in:

  14. Search for Tobias Kessler in:

  15. Search for Anna von Landenberg in:

  16. Search for Anna S. Berghoff in:

  17. Search for Kelly Marsh in:

  18. Search for Mya Steadman in:

  19. Search for Dongwei Zhu in:

  20. Search for Brandon Nicolay in:

  21. Search for Benedikt Wiestler in:

  22. Search for Michael O. Breckwoldt in:

  23. Search for Ruslan Al-Ali in:

  24. Search for Simone Karcher-Bausch in:

  25. Search for Matthias Bozza in:

  26. Search for Iris Oezen in:

  27. Search for Magdalena Kramer in:

  28. Search for Jochen Meyer in:

  29. Search for Antje Habel in:

  30. Search for Jessica Eisel in:

  31. Search for Gernot Poschet in:

  32. Search for Michael Weller in:

  33. Search for Matthias Preusser in:

  34. Search for Minou Nadji-Ohl in:

  35. Search for Niklas Thon in:

  36. Search for Michael C. Burger in:

  37. Search for Patrick N. Harter in:

  38. Search for Miriam Ratliff in:

  39. Search for Richard Harbottle in:

  40. Search for Axel Benner in:

  41. Search for Daniel Schrimpf in:

  42. Search for Jürgen Okun in:

  43. Search for Christel Herold-Mende in:

  44. Search for Sevin Turcan in:

  45. Search for Stefan Kaulfuss in:

  46. Search for Holger Hess‐Stumpp in:

  47. Search for Karen Bieback in:

  48. Search for Daniel P. Cahill in:

  49. Search for Karl H. Plate in:

  50. Search for Daniel Hänggi in:

  51. Search for Marion Dorsch in:

  52. Search for Mario L. Suvà in:

  53. Search for Barbara A. Niemeyer in:

  54. Search for Andreas von Deimling in:

  55. Search for Wolfgang Wick in:

  56. Search for Michael Platten in:

Contributions

L.B., S.P., and T.B. designed and performed experiments, analyzed data, and wrote the paper. F.S. and A.v.D. provided glioma tissue, determined IDH1 status, provided tissue stainings, and performed 850 k methylation arrays. K.S., M.F., M.Ki., A.v.L., and S.K.-B. performed in vitro experiments. J.K.S., M.Kr., and I.O. performed in vivo experiments. D.A. and B.A.N. performed calcium and respiration measurements. E.G., M.B., and R.H. performed genetic modification of cell lines. K.D. analyzed primary human tissue. C.N., M.L.S., S.U., and K.B. were involved in TIL processing. T.K. and D.S. analyzed RNA-seq data. A.S.B. and M.Pr. provided glioma tissue, determined IDH1 status, and provided immunohistochemistry stainings. K.M., M.S., D.Z., B.N., and M.D. performed metabolomics and interpreted data. B.W. performed statistical and TCGA analyses. M.O.B. performed magnetic resonance imaging. R.A.-A. and S.T. performed epigenetic profiling. J.M. and A.H. performed RNA-seq. G.P. performed adenosine phosphate and polyamine measurements. M.W. provided glioma tissues and was involved in data interpretation. M.N.-O., N.T., M.C.B., P.N.H., M.R., D.P.C., K.H.P., and D.H. provided glioma tissue. A.B. performed KEGG pathway analyses. J.E. and J.O. performed R-2-HG measurements. C.H.-M. provided the primary glioma cell line. S.K. and H.H.-S. interpreted data and provided BAY1436032. W.W. was involved in study design and data interpretation. M.Pl. conceptualized the study, interpreted data, and wrote the paper.

Competing interests

M.Pl., W.W., and T.B. are inventors on a patent application entitled ‘Means and methods for treating or diagnosing IDH1R132H mutant-positive cancers’ (WO 2013/102641 A1, PCT/EP2013/050048). S.P. and A.v.D. are eligible to royalties as co-inventors of BAY 1436032 and are patent holders of ‘Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG)’ (WO2013127997A1). This patent is under the administrative supervision of the DKFZ technology transfer office. K.M., M.S., D.Z., B.N., and M.D. are full-time employees of Agios. S.K. and H.H.S. are full-time employees of Bayer. The other authors declare no conflict of interest. Requests for materials should be addressed to m.platten@dkfz.de.

Corresponding author

Correspondence to Michael Platten.

Supplementary information

  1. Supplementary Text and Figures

    Supplementary Figures 1–10 and Supplementary Tables 1–5

  2. Reporting Summary

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41591-018-0095-6